Evolent Health, Inc. (NYSE:EVH) Receives $21.92 Consensus Price Target from Brokerages

Shares of Evolent Health, Inc. (NYSE:EVH) have received a consensus rating of “Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $18.54.

Several equities analysts have commented on the company. UBS Group cut their price objective on Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. Barclays cut their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Oppenheimer decreased their price objective on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating for the company in a report on Friday. BTIG Research dropped their target price on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, December 3rd. Finally, Canaccord Genuity Group decreased their price target on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday.

Institutional Trading of Evolent Health

Several hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its position in Evolent Health by 12.8% during the third quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after acquiring an additional 1,426,747 shares during the last quarter. Engaged Capital LLC increased its position in shares of Evolent Health by 26.1% during the second quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company’s stock worth $78,611,000 after purchasing an additional 850,000 shares in the last quarter. Eventide Asset Management LLC lifted its holdings in shares of Evolent Health by 1.7% during the 3rd quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock valued at $107,580,000 after purchasing an additional 64,985 shares during the last quarter. State Street Corp boosted its position in shares of Evolent Health by 1.0% in the 3rd quarter. State Street Corp now owns 2,725,375 shares of the technology company’s stock worth $77,074,000 after purchasing an additional 25,967 shares in the last quarter. Finally, Bellevue Group AG increased its position in Evolent Health by 59.9% during the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock valued at $75,509,000 after buying an additional 1,000,215 shares in the last quarter.

Evolent Health Trading Down 0.7 %

EVH stock opened at $10.11 on Monday. Evolent Health has a twelve month low of $9.74 and a twelve month high of $35.00. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -11.10 and a beta of 1.45. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The firm’s fifty day simple moving average is $11.45 and its two-hundred day simple moving average is $20.38.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 7th. The technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The firm had revenue of $621.40 million for the quarter, compared to the consensus estimate of $625.58 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. As a group, analysts anticipate that Evolent Health will post 0.26 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.